Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Pfleiderer

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Pharmazie in Unserer Zeit|June 3, 2011
[Flu vaccines]Michael Pfleiderer
Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt Fur Sera Und Impfstoffe) Zu Frankfurt A.M|March 31, 2007
Marketing authorization for recombinant products in EuropeMichael Pfleiderer
Pharmazie in Unserer Zeit|December 18, 2007
[Production and quality control of vaccines]Michael Pfleiderer
Biologicals : Journal of the International Association of Biological Standardization|September 24, 2009
Stability of vaccines - bridging from stability data to continuous safety and efficacy throughout shelf life - an always reliable approach?Michael Pfleiderer
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|January 9, 2015
[From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks]Michael Pfleiderer, Ole Wichmann
Expert Review of Vaccines|September 26, 2012
Reproducibility of assays for influenza vaccine immunogenicity determination: progress towards consistencyRalf Wagner, Michael Pfleiderer
Vaccine|March 28, 2018
Official batch control of influenza vaccines: Is it still useful?Evelyne Kretzschmar, Heide Muckenfuss, Michael Pfleiderer
Deutsches Arzteblatt International|May 28, 2009
Vaccination safety updateBurkhard Schneeweiss, Michael Pfleiderer, Brigitte Keller-Stanislawski
Nature Biotechnology|September 11, 2010
First-in-human clinical trials with vaccines--what regulators wantKaren B Goetz, Michael Pfleiderer, Christian K Schneider
Vaccine|July 31, 2017
The value of multi-country joint regulatory reviews: The experience of a WHO joint technical consultation on the CYD-TDV (Dengvaxia®) dossierKirsten Vannice, Liliana Chocarro, Michael Pfleiderer, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmazie in Unserer Zeit|June 3, 2011
[Flu vaccines]Michael Pfleiderer
Arbeiten Aus Dem Paul-Ehrlich-Institut (Bundesamt Fur Sera Und Impfstoffe) Zu Frankfurt A.M|March 31, 2007
Marketing authorization for recombinant products in EuropeMichael Pfleiderer
Pharmazie in Unserer Zeit|December 18, 2007
[Production and quality control of vaccines]Michael Pfleiderer
Biologicals : Journal of the International Association of Biological Standardization|September 24, 2009
Stability of vaccines - bridging from stability data to continuous safety and efficacy throughout shelf life - an always reliable approach?Michael Pfleiderer
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|January 9, 2015
[From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks]Michael Pfleiderer, Ole Wichmann
Expert Review of Vaccines|September 26, 2012
Reproducibility of assays for influenza vaccine immunogenicity determination: progress towards consistencyRalf Wagner, Michael Pfleiderer
Vaccine|March 28, 2018
Official batch control of influenza vaccines: Is it still useful?Evelyne Kretzschmar, Heide Muckenfuss, Michael Pfleiderer
Deutsches Arzteblatt International|May 28, 2009
Vaccination safety updateBurkhard Schneeweiss, Michael Pfleiderer, Brigitte Keller-Stanislawski
Nature Biotechnology|September 11, 2010
First-in-human clinical trials with vaccines--what regulators wantKaren B Goetz, Michael Pfleiderer, Christian K Schneider
Vaccine|July 31, 2017
The value of multi-country joint regulatory reviews: The experience of a WHO joint technical consultation on the CYD-TDV (Dengvaxia®) dossierKirsten Vannice, Liliana Chocarro, Michael Pfleiderer, et al.
Pageof 2